Series A2 bridge · Healthtech
ImpriMed raises $10m Series A2 bridge led by LB Investment
New investors NAVER D2SF, Samsung Securities and Alois Ventures joined existing backers.
ImpriMed raised $10 million in Series A2 bridge financing led by LB Investment. NAVER D2SF, Samsung Securities and Alois Ventures joined existing investors BonAngels and Han River Partners.
The funding will advance U.S. commercialization and Asian expansion. ImpriMed is preparing U.S. products for blood cancers and blood infections, with FDA clearance and CLIA certification targeted for 2027; its veterinary drug-response service is already operating.
Use of funds
Advance U.S. commercialization
Expand in Asia
Funding history
Series A2 bridge · This round$10M